IPHA IPHA
Company Profile ↓Company Overview
IPHA (IPHA) is a publicly traded company listed on with a market capitalization of $165.88M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $2.79M (-77.9% YoY); net profit $-49.18M.
- Trailing 12 Months Year-on-year growth — revenue -77.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -61.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -61.69% |
| 1 Year: | -77.92% |
Stock Price Performance
| 1 Year: | -17.48% |
| 6 Months: | -0.56% |
| 3 Months: | +26.43% |
| 1 Month: | -6.84% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)49.82 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -61.7% CAGR over 5 years.
- Trading 25.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 49.58M | 51.90M | 12.62M | 2.79M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 66.00M | 64.57M | 64.20M | 56.21M |
| Operating Income | -16.43M | -12.67M | -51.58M | -53.42M |
| EBITDA | -12.28M | -5.55M | -46.91M | -43.65M |
| Interest Expense | 288.00K | 640.00K | 566.00K | 440.00K |
| Pretax Income | -57.97M | -7.57M | -49.47M | -49.18M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -58.10M | -7.57M | -49.47M | -49.18M |
| Diluted EPS | -0.73 | -0.09 | -0.61 | -0.55 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 199.29M | 175.19M | 111.06M | 62.72M |
| Current Assets | - | 139.83M | 148.01M | 85.74M | 46.71M |
| Cash & Equivalents | - | 84.22M | 70.61M | 66.40M | 28.09M |
| Inventory | - | - | - | - | - |
| Receivables | - | 3.08M | 15.23M | 650.00K | 391.00K |
| Total Liabilities | - | 145.14M | 123.29M | 102.22M | 84.42M |
| Current Liabilities | - | 41.34M | 39.64M | 32.98M | 36.65M |
| Long Term Debt | - | 38.93M | 30.61M | 22.18M | 13.67M |
| Total Debt | - | 42.25M | 39.89M | 31.00M | 22.57M |
| Total Equity | - | 54.15M | 51.90M | 8.83M | -21.70M |
| Shares Outstanding | - | 79.54M | 80.86M | 83.83M | 93.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -19.16M | -52.76M | -6.90M | -32.56M |
| Investing Cash Flow | - | 1.88M | 7.29M | 9.20M | 20.63M |
| Financing Cash Flow | - | -1.83M | 6.07M | -6.01M | -1.97M |
| Capital Expenditure | - | -1.12M | -140.00K | -391.00K | -2.35M |
| Free Cash Flow | - | -20.28M | -52.90M | -7.29M | -34.91M |
| Net Change in Cash | - | -19.10M | -39.40M | -3.70M | -13.89M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -33.1% | -24.4% | -408.7% | -1,916.9% |
| Net Margin % | -117.2% | -14.6% | -392.0% | -1,764.5% |
| ROE % | -107.3% | -14.6% | -560.0% | 226.6% |
| ROCE % | -10.4% | -9.3% | -66.1% | -204.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IPHA
Innate Pharma: Pipeline Optionality Favors Speculative Bulls At These Levels - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOUlNsQ0hvN2o4M3FPMWFhaE0zNmRaSlk5VVJrOVIxMVNxQzl6WWt5bC0tTlB6azlTM0k4VjdmT2dkc3ZHTEJ2NjFHd0lHanExU2l2bHM2SmRCbUxBZzZLNU1SLTNDN1JXU2VzYVpTRmNWSktsZDRsa2NpT0x2UVNzTTJ2ZUVmS1VHallOeS…
Bladder cancer treatment panel to feature Innate Pharma CMO - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPZmFuSU82R2p4ZW9rLUlIYldrbjVRRUFycUF0SUdYZFR3LXlZM0lIN3NCbVRQYUhkU1lJdXdBN1RlNjFEdkNYU3hwWmtJYzMtRGFMc2swMlZhQndfbklVeHA4dDJ1UmxreF9QdklNN2FYY0d2eDRTWVdjMGMtMl9YRS1GYWtYLUY4NEJvNm…
Innate Pharma's IPH4502 Reports Responses in Three Tumor Types - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQeUlWTzYyZUJiOGNEZkxNQ013SkZER1BRWmFlTkpjT1F0VjFlYUprQ2dJN0lrb2ZLYjQyS0dScDRZaXo1bE5TRVBFRU9uT3gxMnlIVGtkQndhUnV3WUktWmJsRUpHakZxbUx5SHk1ZWd3U0kzeW9Vd3VZNmNiVWJ3eXViTFVRTWRqN0dMZ0…
IPHA|Innate Pharma SA|Price:1.745| - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9zamhjNjhQNEZSWEhNQUozcmNJUUZFRjJWZnlxeWhzNzNxOTdSb3hoT3Vpbk50QmlNY0dGU3hXdWlGNGFhLUluaTJLQWVwWGpZNFVzUEVEdTBIa0VPRHUxN3czbzdpZ0p0TFFKQS1B?oc=5" target="_blank">IPHA|Innate Pharma …
Innate Pharma (IPHA) Edges Higher Near Key Support; Resistance at $1.88 in Focus - Analyst Downgrade Signals - po-news-eg.net
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQWdsN3RfSHdkMDVyRW10czdpQVh6VERXa1VfcDg4OWs1WkQ2WTVPYUJidmtZaW8tM0RkSDJqbHM2X2ZUV2ZLY0J3Wnp2VHVNUkM5LW1qSnVSeS15X0xBQ0Uwb20yZlBaQ01XSGZVS0gxeFZhYVF0bmV6ZjlOMjQzSXI5ZGRKSUdlMThNQV…
Innate Pharma (IPHA) Dips 1.4% as Stock Nears Key Support Level - ATR Trailing Stop - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQbUdrMzF0enRRRllEVzh6V3FpQUVNU3FiS1pWNUVuNDRuSHlVaVk5dzFOX2hKaWw3Z2xEUUZtTmhIMDhQZDRQdmtucERMUlM0NWtqZF9GamV2d2ZTU2dHUnBWZ1hOTEVKR2dUYk05a1NtS1RtWnpQNXlaY0w4S0dYV0JtMEpoT1QzSG1XRl…
IPHA — Frequently Asked Questions
What is the current share price of IPHA?
As of 2026-08-05 17:25 PDT, IPHA trades at $1.77 on NASDAQ/NYSE. Its 52-week range is $1.17 to $2.38.
What is the market capitalisation of IPHA?
IPHA has a market capitalisation of $165.88M on NASDAQ/NYSE.
What is the P/E ratio of IPHA?
IPHA trades at a trailing price-to-earnings (P/E) ratio of -3.22. Its price-to-book (P/B) ratio is -7.64.
Is IPHA a good stock to buy?
This page provides a data-driven analysis of IPHA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.